Compounds > landomycin a
Page last updated: 2024-11-12

landomycin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

landomycin A: structure given in first source; isolated from Streptomyces sp. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9988748
CHEMBL ID1668770
CHEBI ID70064
MeSH IDM0178064

Synonyms (7)

Synonym
landomycin a
chebi:70064 ,
CHEMBL1668770
C18822
(6r)-1,6,11-trihydroxy-8-[(2s,4r,5s,6r)-4-hydroxy-5-[(2s,4r,5r,6r)-5-hydroxy-4-[(2s,5s,6s)-5-[(2s,4r,5s,6r)-4-hydroxy-5-[(2s,4r,5r,6r)-5-hydroxy-4-[(2s,5s,6s)-5-hydroxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]ox
Q27138403
AKOS040746990

Research Excerpts

Overview

Landomycin A (LA) is a new antitumor antibiotic of angucycline group. LA induces early apoptosis in target cells.

ExcerptReferenceRelevance
"Landomycin A (LA) is a new antitumor antibiotic of angucycline group, possessing high antitumor activity against cancer cells of different origin, which induces early apoptosis in target cells. "( THE ROLE OF REACTIVE OXYGEN SPECIES IN TUMOR CELLS APOPTOSIS INDUCED BY LANDOMYCIN A.
Berger, W; Lehka, LV; Panchuk, RR; Rohr, J; Stoika, RS, )		1.81

Actions

ExcerptReferenceRelevance
"Landomycin A was found to inhibit the uptake of [3H]thymidine into DNA in murine smooth muscle cells indicating decreased DNA synthesis. "( Landomycin A inhibits DNA synthesis and G1/S cell cycle progression.
Crow, RT; Guo, Y; Ramos, KS; Rosenbaum, B; Smith, R; Sulikowski, GA, 1999)		3.19
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
oligosaccharideA compound in which monosaccharide units are joined by glycosidic linkages. The term is commonly used to refer to a defined structure as opposed to a polymer of unspecified length or a homologous mixture. When the linkages are of other types the compounds are regarded as oligosaccharide analogues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID142454Inhibition of uptake of [3H]thymidine into DNA by murine smooth cells at a concentration of 200 nM after 16 hours1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Landomycin A inhibits DNA synthesis and G1/S cell cycle progression.
AID142461Inhibition of uptake of [3H]-thymidine into DNA by murine smooth cells at a concentration of 80 nM after 20 hours1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Landomycin A inhibits DNA synthesis and G1/S cell cycle progression.
AID1755129Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by resazurin dye based fluorescence analysis2021Journal of natural products, 07-23, Volume: 84, Issue:7
Himalaquinones A-G, Angucyclinone-Derived Metabolites Produced by the Himalayan Isolate
AID1755128Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by resazurin dye based fluorescence analysis2021Journal of natural products, 07-23, Volume: 84, Issue:7
Himalaquinones A-G, Angucyclinone-Derived Metabolites Produced by the Himalayan Isolate
AID142460Inhibition of uptake of [3H]thymidine into DNA by murine smooth cells at a concentration of 80 nM after 16 hours1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Landomycin A inhibits DNA synthesis and G1/S cell cycle progression.
AID142456Inhibition of uptake of [3H]thymidine into DNA by murine smooth cells at a concentration of 200 nM after 24 hours1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Landomycin A inhibits DNA synthesis and G1/S cell cycle progression.
AID142458Inhibition of uptake of [3H]thymidine into DNA by murine smooth cells at a concentration of 20 nM after 20 hours1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Landomycin A inhibits DNA synthesis and G1/S cell cycle progression.
AID678076Growth inhibition of human NCI-H460 cells incubated for 48 hrs by resazurin dye reduction based fluorimetric assay2012Journal of natural products, Jul-27, Volume: 75, Issue:7
Saquayamycins G-K, cytotoxic angucyclines from Streptomyces sp. Including two analogues bearing the aminosugar rednose.
AID568575Cytotoxicity against ER-refractory human MDA231 cells after 24 hrs by trypan blue staining2011Journal of natural products, Jan-28, Volume: 74, Issue:1
Landomycins P-W, cytotoxic angucyclines from Streptomyces cyanogenus S-136.
AID1755130Inhibition of 4E-BP1 phosphorylation in human HCT116 cells at 2 uM after 6 hrs by Western blot analysis2021Journal of natural products, 07-23, Volume: 84, Issue:7
Himalaquinones A-G, Angucyclinone-Derived Metabolites Produced by the Himalayan Isolate
AID678075Growth inhibition of human PC3 cells incubated for 48 hrs by resazurin dye reduction based fluorimetric assay2012Journal of natural products, Jul-27, Volume: 75, Issue:7
Saquayamycins G-K, cytotoxic angucyclines from Streptomyces sp. Including two analogues bearing the aminosugar rednose.
AID568574Cytotoxicity against ER-positive human MCF7 cells after 24 hrs by trypan blue staining2011Journal of natural products, Jan-28, Volume: 74, Issue:1
Landomycins P-W, cytotoxic angucyclines from Streptomyces cyanogenus S-136.
AID142459Inhibition of uptake of [3H]thymidine into DNA by murine smooth cells at a concentration of 20 nM after 24 hours1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Landomycin A inhibits DNA synthesis and G1/S cell cycle progression.
AID142455Inhibition of uptake of [3H]thymidine into DNA by murine smooth cells at a concentration of 200 nM after 20 hours1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Landomycin A inhibits DNA synthesis and G1/S cell cycle progression.
AID142457Inhibition of uptake of [3H]thymidine into DNA by murine smooth cells at a concentration of 20 nM after 16 hours1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Landomycin A inhibits DNA synthesis and G1/S cell cycle progression.
AID142462Inhibition of uptake of [3H]thymidine into DNA by murine smooth cells at a concentration of 80 nM after 24 hours1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Landomycin A inhibits DNA synthesis and G1/S cell cycle progression.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (7.89)18.2507
2000's17 (44.74)29.6817
2010's16 (42.11)24.3611
2020's2 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.41 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (7.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (92.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
galactose
aldohexose : A hexose with a (potential) aldehyde group at one end.		210
chrysomycin a
chrysomycin A: Streptomyces arenae; differs only in sugar moiety from gilvocarcin V		3.1710glycoside
tetrangulol
tetrangulol: structure in first source. tetrangulol : A member of the class of tetraphenes that is tetraphene-7,12-dione substituted by hydroxy groups at positions 1 and 8 and a methyl group at position 3.		2.7430p-quinones;
phenols;
tetraphenes		bacterial metabolite
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		2.0610
ay 25545
ravidomycin: isolated from mycelium of Streptomyces ravidus; structure given in first source. ravidomycin : A C-glycosylated naphthoisochromene derivative obtained from Streptomyces ravidus; exhibits antibiotic and anticancer properties.		3.1710acetate ester;
aromatic ether;
C-glycosyl compound;
naphthoisochromene;
olefinic compound;
phenols;
tertiary amine		antimicrobial agent;
antineoplastic agent;
bacterial metabolite
xylose
xylopyranose: structure in first source		2.0610D-xylose
kerriamycin b
kerriamycin B: from a streptomycete; structure given in first source		2.4820angucycline antibioticantineoplastic agent
glycosides
[no description available]		9.2350
d-glucal
[no description available]		2.0610
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		3.8430
rhodinose
rhodinose: structure in first source		210trideoxyhexose
olivose
olivose: RN given for (D)-isomer		2.0210hexose
gilvocarcin v
gilvocarcin V: from Actinomycete DO-38; structure given in first source		3.1710
jadomycin a
jadomycin A: the aglycone of jadomycin B; structure in first source. jadomycin A : A organic heteropentacyclic compound that is 1,2,8,13-tetrahydro-3aH-benzo[b][1,3]oxazolo[3,2-f]phenanthridine which carries oxo groups at positions 2, 8 and 13, methyl group at position 5, hydroxy groups at positions 7 and 12, and a (2R)-butan-2-yl group at position 1. It is a mixture of epimers at the hemiaminal carbon (position 3a).		3.1710
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		2.0710organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
saquayamycin b
saquayamycin B: isolated from Streptomyces nodosus MH190-16F3; structure given in first source		2.0710
jadomycin b
jadomycin B: structure given in first source; isolated from Streptomyces venezuelae. jadomycin B : A jadomycin that is jadomycin A in which the phenolic hydroxy group at position 12 has been converted to the corresponding 2,6-dideoxy-alpha-L-ribo-hexopyranoside, isolated from Streptomyces venezuelae. It exists as a diastereoisomeric mixture consisting of both 3aS and 3aR isomers.		3.1710glycoside;
jadomycin;
organic heteropentacyclic compound		antibacterial agent;
antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor;
bacterial metabolite
landomycinone
landomycinone: structure in first source		7.4420
landomycin d
landomycin D: structure in first source		2.7430anthraquinonemetabolite
landomycin e
landomycin E: structure given in first source; isolated from Streptomyces sp.		4.5470oligosaccharide
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		3.1710benzenes;
hydroxycoumarin;
methyl ketone
chrysomycin b
chrysomycin B: structure given in first source		3.1710
kinamycin a
kinamycin A: isolated from Streptomyces muragamaensis; RN in Chemline for Kinamycin B: 35303-13-0; RN for Kinamycin C: 35303-08-3; RN for Kinamycin D: 35303-14-1; RN given refers to parent cpd; structure		3.1710kinamycin
kinamycin f
kinamycin F: isolated from Streptomyces murayamaensis; structure given in first source		3.1710kinamycin
angucyclinone
angucyclinone: structure in first source		3.1710
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		03.8520
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.8520
Carcinoma, Non-Small Cell Lung
[description not available]		02.0710
Cancer of Lung
[description not available]		02.0710
Cancer of Prostate
[description not available]		02.0710
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.0710
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0710
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0710